Drug Guidance for Subsidy 06/02/2026 Capivasertib in combination with fulvestrant for HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration NRThe Ministry of Health’s Drug Advisory Committee has not recommended capivasertib in combina... See all × 06/02/2026 Capivasertib in combination with fulvestrant for HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration NRThe Ministry of Health’s Drug Advisory Committee has not recommended capivasertib in combination with fulvestrant for inclusion on the MOH List of Subsidised Drugs for HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration following disease recurrence or progression on or after an endocrine-based regimen with or without a cyclin-dependant kinase 4/6 inhibitor (CDK4/6i). The decision was based on the uncertain extent of clinical benefit compared with fulvestrant monotherapy, unfavourable cost effectiveness compared with alternative treatments, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for capivasertib are provided in the Annex.
ORAL Select a brand starting with the letter: T TRUQAP FILM-COATED TABLETS 160MG [SIN17112P] TRUQAP FILM-COATED TABLETS 200MG [SIN17111P]